Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 6
2014 2
2016 1
2018 1
2019 1
2021 1
2022 2
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Chapple CR, et al. Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11. Neurourol Urodyn. 2014. PMID: 24127366 Review.
This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date. METHODS: All clinical data on mirabegron that are currently in the public domain are included, including some in-press manuscripts. ...In OAB clinical tri …
This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date. METHODS: All clinical …
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Kennelly MJ, et al. Adv Ther. 2021 Nov;38(11):5452-5464. doi: 10.1007/s12325-021-01902-8. Epub 2021 Sep 18. Adv Ther. 2021. PMID: 34537953 Free PMC article.

Vibegron showed significantly greater reduction in mean daily number of total incontinence episodes than mirabegron 25 mg at week 4, mirabegron 50 mg (weeks 4, 52), and tolterodine (weeks 4, 12) (P < 0.05, each) and significantly greater improvement in volume voi

…
Vibegron showed significantly greater reduction in mean daily number of total incontinence episodes than mirabegron 25 mg at week 4, …
Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Krauwinkel W, et al. Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010. Clin Ther. 2012. PMID: 23063375 Clinical Trial.
Mirabegron was generally well tolerated up to 300 mg once daily. No clear trends for increased incidence of AEs occurred with higher doses of mirabegron. The AE with the highest incidence was headache. CONCLUSION: Oral mirabegron exhibited a greater-th …
Mirabegron was generally well tolerated up to 300 mg once daily. No clear trends for increased incidence of AEs occurred with higher …
Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
Wang J, Zhang A, Ye M, Zhang C. Wang J, et al. Front Pharmacol. 2024 Mar 18;15:1376535. doi: 10.3389/fphar.2024.1376535. eCollection 2024. Front Pharmacol. 2024. PMID: 38562462 Free PMC article.
However, AEs were still possible after 1 year of mirabegron treatment. Conclusion: This study provided valuable evidence for the real-world safety of mirabegron, helping clinical professionals enhance their understanding of mirabegron's safety in clinical pra …
However, AEs were still possible after 1 year of mirabegron treatment. Conclusion: This study provided valuable evidence for the real …
Gateways to clinical trials.
Tomillero A, Moral MA. Tomillero A, et al. Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):517-48. doi: 10.1358/mf.2010.32.7.1549223. Methods Find Exp Clin Pharmacol. 2010. PMID: 21069103 Free article.
Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placarbil, Aripiprazole, ARQ-621, Azelnidipine, Azilsartan medoxomil potassium; Bevacizumab, Biphasic insulin aspart, Bortezomib; Choriogonadotro …
Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placa …
Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study.
Dmochowski RR, Rovner ES, Kennelly MJ, Newman DK, Xavier K, Thomas E, Snyder D, Abedinzadeh L. Dmochowski RR, et al. BMC Urol. 2025 Apr 2;25(1):66. doi: 10.1186/s12894-025-01742-6. BMC Urol. 2025. PMID: 40176006 Free PMC article.
Patients were enrolled if they were 18 years of age with OAB, initiating vibegron after previously receiving anticholinergics (Cohort A) or mirabegron with/without anticholinergics (Cohort B). Satisfaction was assessed via the OAB Satisfaction With Treatment Questionnair …
Patients were enrolled if they were 18 years of age with OAB, initiating vibegron after previously receiving anticholinergics (Cohort A) o …
Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder.
Liao CH, Kuo HC. Liao CH, et al. J Formos Med Assoc. 2019 Mar;118(3):700-706. doi: 10.1016/j.jfma.2018.08.014. Epub 2018 Aug 30. J Formos Med Assoc. 2019. PMID: 30172451 Free article. Clinical Trial.
METHODS: A total of 242 patients (mean age: 67 years) with OAB were randomized to two groups: M25 (mirabegron 25 mg daily for 12 weeks) and M50 (mirabegron 25 mg daily for 4 weeks + 50 mg daily for 8 weeks). ...Adverse event (AE) rates were similar between th …
METHODS: A total of 242 patients (mean age: 67 years) with OAB were randomized to two groups: M25 (mirabegron 25 mg daily for 12 week …
Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Keirns J. Lee J, et al. Clin Ther. 2013 Mar;35(3):333-41. doi: 10.1016/j.clinthera.2013.02.014. Clin Ther. 2013. PMID: 23497763 Clinical Trial.
Mirabegron was generally well tolerated, with no apparent difference in AE frequency between the fasted and fed states. CONCLUSIONS: Mirabegron OCAS tablets exhibited a decrease in mirabegron plasma exposure with food that was independent of dose (50 o …
Mirabegron was generally well tolerated, with no apparent difference in AE frequency between the fasted and fed states. CONCLU …
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Nitti VW, et al. Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21. Int J Clin Pract. 2013. PMID: 23692526 Free PMC article.
INTRODUCTION: To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. ...For mirabegron …
INTRODUCTION: To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, …
Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H, Tokuno T, Amada Y, Matsushima H, Katashima M, Sawamoto T, Takusagawa S, van Gelderen M, Tanaka T, Miyahara H. Iitsuka H, et al. Clin Drug Investig. 2014 Jan;34(1):27-35. doi: 10.1007/s40261-013-0146-1. Clin Drug Investig. 2014. PMID: 24178236 Free PMC article. Clinical Trial.
BACKGROUND: Mirabegron is a human beta3-adrenoceptor agonist for the treatment of overactive bladder. ...Mirabegron was generally well-tolerated at single doses up to 400 mg and multiple doses up to 200 mg. ...
BACKGROUND: Mirabegron is a human beta3-adrenoceptor agonist for the treatment of overactive bladder. ...Mirabegron was genera …
16 results